Artrofoon 100 pcs tab

Description

Composition
Active substance:
Antibodies to tumor necrosis factor alpha human affinity-purified – 0,003 * g.
* Applied to the lactose as a water-alcohol mixture with a content of no more than 10-15 ng / g of the active form of the active ingredient.
Excipients:
Lactose monohydrate (Lactose) 0.267 g, 0.03 g of microcrystalline cellulose, magnesium stearate 0.003 g
Description:
Tablets ploskotsilindricheskoy shape, with the notch and chamfer, from white to almost white color. On the flat side coated with Valium inscription MATERIA MEDICA, on the other flat side applied ARTHROFON inscription.
Product form:
Lozenges. 20 tablets in blisters of PVC film and aluminum foil.
5 the contour of cellular packaging together with instructions for medical application is placed in a pile of cardboard.
Contraindications
Increased individual sensitivity to the drug.
Not recommended for use in children and adolescents under the age of 18 years (due to lack of clinical experience).
Indications
Rheumatoid arthritis, osteoarthritis (including spondylarthritis) and other joint diseases. The period of remission is possible to use the drug in the composition monotherapy in exacerbation – in combined therapy (with non-steroidal anti-inflammatory drugs).
Ulcerative colitis mild to moderate severity.
Interaction with other drugs
Cases of incompatibility with other drugs has not yet been registered. Perhaps a combination of medication with NSAIDs.
Overdose
Accidental overdosing possible diarrheal phenomena caused by members of the formulation excipients.
pharmachologic effect
Pharmacological group:
Anti-inflammatory agent. Immunomodulatory agent.
Pharmacodynamics:
Experimentally and clinically proven drug that modulates the production and functional activity of endogenous tumor necrosis factor alpha (TNF alpha) rheumatoid arthritis, osteoarthrosis, osteochondrosis, backache; ulcerative colitis (UC). It has anti-inflammatory and analgesic effect. By reducing the production of some pro-inflammatory cytokines, mediators of inflammation inhibits the progression of inflammatory tissue damage and target organs in inflammatory and degenerative joint diseases and ulcerative colitis.
Pharmacokinetics:
Sensitivity modern physico-chemical methods of analysis (gas-liquid chromatography, high performance liquid chromatography, gas chromatography-mass spectrometry) do not allow to evaluate the content of ultra-low doses of antibodies in biological fluids, organs and tissues, making it impossible to study the pharmacokinetics technically Artrofoon preparation.
Pregnancy and breast-feeding
Security applications Artrofoona in pregnancy and lactation has not been studied. If necessary, dosing should be considered risk / benefit ratio.
Conditions of supply of pharmacies
Without recipe.
side effects
Possible reactions of individual hypersensitivity to the drug.
special instructions
3-5 hours after the start of treatment may moderately pronounced transient increase in pain or local manifestations of inflammation, which does not require changes in the pharmacotherapy regime. In some cases, when expressed amplification of pain or local inflammation symptoms necessary to temporarily reduce the dose to 1 – 2 tablets per day.
The preparation includes lactose, in connection with which it is not recommended for patients with congenital galactosemia, malabsorption of glucose or galactose, or with congenital lactase deficiency.
Effect on the vehicles ability to drive
Artrofoon does not affect the ability to drive vehicles and other potentially dangerous machinery.
Storage conditions
At temperatures above 25 ° C. Keep out of reach of children. During the period of the drug storing contour cell pack in a cardboard bundle provided by the manufacturer.
Dosing and Administration
Inside. At one time – 2 tablets (kept in the mouth until complete dissolution – not during a meal).
Rheumatoid arthritis, osteartroz (including spondylarthritis) and other joint diseases.
The drug is taken twice a day, morning and evening (before and after sleep). The recommended duration of dosing – up to 6 months.
When expressed pain syndrome in the first 2 – 4 weeks of therapy is recommended taking the drug up to 4 times a day, as part of combination therapy. While improving the state gradually go to the reception of 2 tablets 2 times a day.
Nonspecific ulcerative colitis.
The drug is taken twice a day, morning and evening (before and after sleep).
The recommended duration of dosing – up to 6 months.
In marked exacerbation of the disease (abdominal pain, diarrhea) in the first 2-4 weeks of therapy recommended intake of the drug up to 4 times a day. While improving the state go to the reception of 2 tablets 2 times a day.
Information
Appearance may differ from that depicted in the picture. There are contraindications. You need to read the manual or consult with a specialist